Takeda Pharmaceutical's strong earnings, dividends, and strategic moves make it an appealing investment despite US policy ...
Q3 2025 Earnings Call Transcript January 30, 2025 Christopher O’Reilly: [Foreign Language] Let me start, I’d like to remind ...
Takeda is promoting U.S. chief Julie Kim to be its next CEO. AstraZeneca and Daiichi's Enhertu has won an FDA nod to expand into HER2-ultralow breast cancer. East Asian Americans are ...
Fourth Quarter and Full Year 2024 Net Product Sales of $615 Million and $2.3 Billion, Representing Year-Over-Year Growth of 23% and 26% Respectively INGREZZA® (valbenazine) Full Year 2025 Net Product ...
Cancer patients, including those on patient assistance programmes, can look forward to some relief on their imported medicines. Medicines from multinational companies including Pembrolizumab (MSD ...
Evox Therapeutics is the second UK biotech to sign a big deal with a pharma giant this week, snaring an $882 million partnership with Takeda for up to five rare disease programmes. The alliance ...
Takeda has officially taken over Shire in a deal that could re-establish the trend for mega mergers in big pharma. The merger was approved yesterday in a court hearing in Jersey, where Shire was ...
Subin Baral, EY global life sciences deals leader, told GEN M&A deals are expected to increase in 2025, driven by biopharmas that are eager to recoup revenues they expect to lose as their aging ...
Stock Market today: The Benchmark Nifty 50 index and the S&P BSE index ended Thursday with gains of 0.37% and 0.30%, respectively, at 23,249.50 and 76,759.81. The Bank Nifty, at 49,311.95, rose 0. ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback